TELA Bio stockholders elect Lisa Colleran and Doug Evans as Class I directors; ratify KPMG as auditor

TELA Bio, Inc.

Lisa Colleran elected with 14,316,642 votes for and 1,055,675 withheld; Doug Evans with 13,535,182 for and 1,837,135 withheld.
Ratification of KPMG as independent auditor for FY2023 passed with 17,188,505 for, 3,312 against, 1,957 abstentions.
Total shares outstanding at April 5, 2023 record date: 19,227,777; broker non-votes on director election: 1,821,457.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TELA Bio, Inc. shareholders approved Election of Class I Directors at the 2023-06-01 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Each of Lisa Colleran and Doug Evans were elected to the Board to serve as Class I directors until the 2026 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Lisa Colleran 14,316,642 1,055,675 1,821,457 Doug Evans 13,535,182 1,837,135 1,821,457

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TELA Bio, Inc. shareholders approved Ratification of Independent Registered Public Accountants at the 2023-06-01 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,188,505 3,312 1,957 –

View on SEC.gov

Browse all shareholder votes →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-067533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.